Palatin Technologies, Inc. (LON:0KF3)
0.986
-0.006 (-0.60%)
At close: Feb 21, 2025
Palatin Technologies Revenue
Palatin Technologies had revenue of $350.00K USD in the twelve months ending December 31, 2024, down -95.07% year-over-year. In the fiscal year ending June 30, 2024, Palatin Technologies had annual revenue of $4.49M, down -7.49%.
Revenue (ttm)
$350.00K
Revenue Growth
-95.07%
P/S Ratio
n/a
Revenue / Employee
$11.67K
Employees
30
Market Cap
20.57M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 4.49M | -363.59K | -7.49% |
Jun 30, 2023 | 4.85M | 3.39M | 230.53% |
Jun 30, 2022 | 1.47M | 1.66M | -878.62% |
Jun 30, 2021 | -188.60K | -306.59K | -259.84% |
Jun 30, 2020 | 117.99K | -60.18M | -99.80% |
Jun 30, 2019 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Jun 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 43.19B |
GSK plc | 31.38B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
Hikma Pharmaceuticals | 2.39B |
ConvaTec Group | 1.74B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Palatin Technologies News
- 16 days ago - Palatin Technologies prices 4.69M shares in direct offering - Seeking Alpha
- 16 days ago - Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement - PRNewsWire
- 17 days ago - Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide - PRNewsWire
- 26 days ago - Palatin Provides Update on Anticipated 2025 Corporate Milestones - PRNewsWire
- 2 months ago - Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy - PRNewsWire
- 2 months ago - Palatin Technologies announces warrant exercise for ~$3.4M gross proceeds - Seeking Alpha
- 2 months ago - Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds - PRNewsWire
- 3 months ago - Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis - PRNewsWire